Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Trijardi XR (empagliflozin + linagliptin + metformin) on glycemic control, weight, vitamin D, and lipid profile in type 2 diabetes
IRCT20240215061021N1Phase 3Completed
- Sponsor
- Dezful University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of empagliflozin + linagliptin + metformin, empagliflozin, linagliptin and metformin in type 2 diabetes mellitus (T2DM), sponsored by Dezful University of Medical Sciences. Primary endpoints: Glycemic control, Body weight and 2 more. Started Feb 2024; status: completed.
02
Drugs
empagliflozin + linagliptin + metforminempagliflozinlinagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20240215061021N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240215061021N1.